Biopharma companies are jumping into partnerships to develop COVID-19 treatments before signing a formal agreement so they can begin research immediately. Attorneys say these deals require caution to address issues that may arise, from liability and intellectual property matters to government funding.
On 2 April, for example, Amgen Inc. and Adaptive Biotechnologies Corp. announced their collaboration to discover and develop antibodies from recovered patients to prevent or treat COVID-19. They...